TY - JOUR T1 - Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study JF - In Vivo JO - In Vivo SP - 2273 LP - 2280 DO - 10.21873/invivo.11733 VL - 33 IS - 6 AU - HYUNKYUNG PARK AU - DONG-YEOP SHIN AU - INHO KIM AU - SANG-KYUN SOHN AU - YOUNGIL KOH AU - JE-HWAN LEE AU - KYOO-HYUNG LEE AU - DAE-YOUNG KIM AU - HYEONG-JOON KIM AU - JAE-SOOK AHN AU - JEONG-OK LEE AU - SOO-MEE BANG AU - JUNE-WON CHEONG AU - SANG-GON PARK AU - SEONYANG PARK AU - YOO JIN LEE AU - SEO-YEON AHN Y1 - 2019/11/01 UR - http://iv.iiarjournals.org/content/33/6/2273.abstract N2 - Background/Aim: Droplet digital polymerase chain reaction (ddPCR) is an exact method of measuring nucleic acids. The aim of this prospective study was to evaluate minimal residual disease (MRD) using ddPCR in chronic myeloid leukemia (CML) patients. Patients and Methods: Between May 2013 and November 2014, CML patients treated with nilotinib were enrolled in our study. BCR/ABL1 transcripts levels were evaluated using ddPCR at the first time of complete molecular response (CMR). We enrolled 15 patients from 7 Institutions. The treatment period and median follow-up period were 45 months and 47 months, respectively. Results: Patients with a high level of BCR/ABL1 transcript had a greater tendency to lose the CMR during the follow-up period (p=0.095). In addition, patients with a low level of BCR/ABL1 transcript showed a longer duration of CMR compared to those with a high level (p=0.032). Conclusion: We found that ddPCR is a sensitive method for detecting MRD and that MRD could affect the duration of the treatment response. ER -